


Pre-analytical phase challenges and biomarker testing in HER2 metastatic breast cancer

HER2 SCORING HAS EVOLVED^{1,2}



HER2 expression now exists on a **continuum**, expanding eligibility for targeted therapies such as **ADCs**

HER2 Scoring by IHC



HER2-low and–ultralow expression now exists on a **continuum**, expanding eligibility for HER2-targeted **ADCs**, such as trastuzumab deruxtecan

PRE-ANALYTICAL QUALITY MATTERS³



High-quality pre-analytical handling and nuanced interpretation are essential for accurate HER2 classification, particularly for HER2-low and–ultralow disease

Small errors in testing or interpretation can lead to missed treatment opportunities particularly in HER2-low or ultra-low disease

Accurate HER2 assessment begins **before the test**

Best practice includes:

- Cold ischaemic time <1 hour
- 10% neutral buffered formalin fixation (6–72 hours)
- Freshly cut slides for staining
- EDTA-based decalcification for bone specimens

TESTING FOR HER2^{2,3}



Immunohistochemistry (IHC): Primary method for HER2 protein expression

In-situ hybridisation (ISH): Confirms HER2 gene amplification in equivocal cases

MULTIDISCIPLINARY COLLABORATION MATTERS⁴



Optimal testing and interpretation require close communication between:

Pathologists, Medical Oncologists, Radiologists, Surgeons, Laboratory Teams, Patients

Accurate biomarker assessment supports **appropriate treatment selection and improved patient outcomes.**

ADCs, antibody-drug conjugates; IHC, immunohistochemistry; ISH, in-situ hybridisation

1. Niu D, et al. Pathology & Oncology Research 2020; 26: 2577-2585;

2. Allison K, et al. College of American Pathologists. Breast Cancer Protocol. March 2025.

Available at: https://documents.cap.org/documents/New-Cancer-Protocols-March-2025/Breast.Bmk_1.6.0.0.REL.CAPCP.pdf;

3. Marabi M; Tse GM. Human Pathology 2025; 162: 105818;

4. Mirham L, et al. Am J Clin Pathol 2021; 156 (4): 521-528